Hydroxynorketamine for the use in the treatment of depression
The present invention relates to hydroxynorketamine for the use in the treatment of depression. In particular, the present invention concerns hydroxynorketamine for use in the treatment of depression, wherein hydroxynorketamine is administered in form of at least one prodrug, and wherein the at least one prodrug is orally administered in a modified-release dosage form. The prodrug is selected from (S)-Ketamine, (R)-Ketamine, (R,S)-Ketamine, (S)-Norketamine, (R)-Norketamine, (R,S)-Norketamine, (S)-Hydroxyketamine, (R)-Hydroxyketamine, (R,S)-Hydroxyketamine.
1. A modified-release dosage form for use in a method for the treatment of depression, to be orally administered, wherein the treatment of depression is a long-term treatment, and wherein the modified-release dosage form is a prolonged-release dosage form, wherein the prolonged-release dosage form is in the form of a diffusion-controlled release system comprising a multitude of particles which are pellets containing a core comprising at least one prodrug of hydroxynorketamine and a release control layer coated upon the core, wherein the at least one prodrug is (R,S)-ketamine hydrochloride and wherein the oral administration of the prolonged-release dosage form comprising (R,S)-ketamine hydrochloride results in plasma concentration profiles exhibiting a ratio of AUC K/HNK between 1:7 and 1:20.
2. The modified-release dosage form for use in a method for the treatment of depression according to claim 1 , wherein the long-term treatment lasts for at least one month.
3. The modified-release dosage form for use in a method for the treatment of depression according to claim 1 , wherein the dosage form is a single-unit or a multiple-unit dosage form.
4. The modified-release dosage form for use in a method for the treatment of depression according to claim 1 , wherein the dosage form is a tablet or a capsule.
5. A method of treating depression, said method comprising orally administering a modified-release dosage form to a patient in need thereof, wherein the treatment of depression is a long-term treatment, and wherein the modified-release dosage form is a prolonged-release dosage form, wherein the prolonged-release dosage form is in the form of a diffusion-controlled release system comprising a multitude of particles which are pellets containing a core comprising at least one prodrug of hydroxynorketamine and a release control layer coated upon the core, wherein the at least one prodrug is (R,S)-ketamine hydrochloride and wherein the oral administration of the prolonged-release dosage form comprising (R,S)-ketamine hydrochloride results in plasma concentration profiles exhibiting a ratio of AUC K/HNK between 1:7 and 1:20.
6. The method of claim 5 , wherein the long-term treatment lasts for at least one month.
7. The method of claim 5 , wherein the dosage form is a single-unit or a multiple-unit dosage form.
8. The method of claim 5 , wherein the dosage form is a tablet or a capsule.
9. The method of claim 5 , wherein the long-term treatment lasts for at least two months.
10. The method of claim 5 , wherein the long-term treatment lasts for at least three months.
11. The method of claim 5 , wherein the dosage form is a tablet.